Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (35)
Guidance programme
(
1 selected
)
Guidance programme
Cancer service guidelines (1)
Clinical guidelines (3)
Diagnostics guidance (2)
Interventional procedures guidance (5)
Medical technologies guidance (1)
NICE guidelines (4)
Technology appraisal guidance (35)
Apply filters
Showing 1 to 10 of 35
Sort by
Date
Title
Apply sorting
breast cancer
Remove breast cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Talazoparib for treating HER2-negative advanced
breast cancer
with germline BRCA mutations
TA952
21 February 2024
21 February 2024
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early
breast cancer
after chemotherapy
TA886
10 May 2023
10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic
breast cancer
after 1 or more anti-HER2 treatments
TA862
1 February 2023
1 February 2023
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced
breast cancer
TA851
14 December 2022
14 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced
breast cancer
after endocrine therapy
TA836
26 October 2022
26 October 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced
breast cancer
after 2 or more therapies
TA819
17 August 2022
17 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced
breast cancer
TA816
10 August 2022
10 August 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early
breast cancer
at high risk of recurrence
TA810
20 July 2022
20 July 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic
breast cancer
TA801
29 June 2022
29 June 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced
breast cancer
after 2 or more anti-HER2 therapies
TA786
27 April 2022
27 April 2022
Current page
1
2
3
4
Page
1
of
4
Next page
Results per page
10
25
50
All
Back to top